A Randomized, Open-label, Phase 3 Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Subjects With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).
收藏DataCite Commons2025-12-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00011988/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review Committee (IRC).
提供机构：
Vivli
创建时间：
2025-12-01
